Lighthouse II Phase 3 update

Lighthouse II is an international clinical trial looking at whether human endogenous retroviruses (HERVs) play a role in MND, and whether the anti-retroviral therapy Triumeq might slow the progression of the disease.

The clinical trial in New Zealand is jointly funded by Motor Neurone Disease NZ and the Neurological Foundation. 

Alan Stanley, Consultant Neurologist and Principal Investigator for the clinical trial, provides an update.

“The Lighthouse II trial is progressing well, and we have 9 participants enrolled across 3 sites. Enrolment has been slower than expected due to staff changes at 3 of the 4 sites. All participants seem to be tolerating the medication well and no safety concerns have been noted. 

“Despite the challenges we have had; achieving almost 50% enrolment is significantly above what has been achieved at most other international centres. This is a testament to the positive spirit of our MND community. We hope to complete enrolment within the next 6 months. 

“My sincere thanks to all our participants and to the MND community for their support and understanding. We are all learning a lot and are building a great foundation for this and future trials.”

Read more about the trial.